AUROPHARMA1,666.00

Aurobindo Pharma Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSUNPHARMADRREDDYCIPLAFORTISLUPINALKEMLAURUSLABSMANKINDMcap ₹96,761 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations29,001.931,723.733,653.134,935.3
Other Income557.4621.9492.1689.5
Total Income29,559.332,345.634,145.235,624.8
Expenses
+ Cost of Materials Consumed10,776.110,736.810,305.210,664.4
+ Purchases of Stock-in-Trade2,772.92,887.13,478.03,602.0
+ Changes in Inventories-946.2-597.6-294.8-390.3
+ Employee Benefit Expense3,922.94,475.65,190.25,441.5
+ Finance Costs289.7457.2384.0387.9
+ Depreciation & Amortisation1,521.71,649.41,778.21,859.3
+ Other Expenses6,633.07,639.18,128.88,532.4
Total Expenses24,970.227,247.628,969.530,097.2
EBITDA5,843.06,582.86,845.77,085.3
EBIT4,321.34,933.45,067.55,226.0
Profit
PBT before Exceptional Items4,589.05,098.05,175.75,527.6
+ Exceptional Items-191.90.0-65.3-105.5
Pretax Income4,397.25,098.05,110.35,422.1
+ Current Tax1,777.51,700.01,736.11,855.4
+ Deferred Tax-566.5-117.3-127.3-146.1
Tax Expense1,211.01,582.71,608.91,709.3
+ Share of Associates & JVs-17.2-31.71.5-1.9
Net Income3,169.03,483.63,503.03,710.8
+ Net Income — Continuing Ops3,186.13,515.33,501.53,712.7
+ Other Comprehensive Income99.2303.61,965.21,512.5
Total Comprehensive Income3,268.13,787.25,468.25,223.3
Net Income to Common3,173.03,485.93,504.83,712.6
Minority Interest-4.0-2.3-1.8-1.8
Per Share
Basic EPS54.1659.8160.3464.00
Diluted EPS54.1659.8160.3464.00
Other Comprehensive Income — detail
+ Other Comprehensive Income303.61,965.21,512.5
+ Items NOT to be Reclassified to P&L-13.6-8.410.95.9
+ Tax on Items NOT to be Reclassified-2.12.73.0
+ Tax on Items NOT to be Reclassified — alt tag-3.0
+ Items to be Reclassified to P&L109.9309.91,957.01,509.6
Comprehensive Income — Owners of Parent3,272.13,789.55,469.95,225.0
Comprehensive Income — Non-controlling Interests-4.0-2.3-1.8-1.8
Per Share — as-filed variants
Basic EPS — Continuing Operations54.1659.8160.3464.00
Diluted EPS — Continuing Operations54.1659.8160.3464.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit16,399.018,697.520,164.721,059.2
Gross Margin %56.5458.9459.9260.28
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)4,589.05,098.05,175.75,527.6
− Exceptional Items (reconciliation)-191.90.0-65.3-105.5
Net Income Adj (tax-effected)3,308.03,483.63,547.73,783.0
EPS Adj56.5459.8161.1165.25
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Paid Up Equity Capital58.658.158.157.5
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.